Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia

Measurable residual disease (MRD) refers to neoplastic cells that cannot be detected by standard cytomorphologic analysis. In patients with acute myeloid leukemia (AML), determining the association of MRD with survival may improve prognostication and inform selection of efficient clinical trial end points.